Utilization of bictegravir/emtricitabine/tenofovir alafenamide in patients with end-stage renal disease on hemodialysis

Abstract

Purpose: The combination antiretroviral bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is a single-tablet, once-daily regimen used in individuals living with HIV; however, its use in the context of renal impairment is uncertain. We report 6 patient cases of BIC/FTC/TAF utilization in individuals with HIV with end-stage renal disease (ESRD) requiring long-term hemodialysis (HD).

Summary: These case reports describe the utilization of BIC/FTC/TAF in individuals with HIV who require chronic HD, the laboratory parameters measured, and patient-reported quality of life and adverse events.

Conclusion: Utilization of BIC/FTC/TAF appears to be an option for individuals with HIV who have ESRD and require long-term HD. This regimen allows for once-daily dosing, elimination of potential serious drug interactions, and simplified patient ART regimens in our patient subset.

Keywords: anti-HIV agents; antiretroviral agents; bictegravir/emtricitabine/tenofovir alafenamide; end-stage renal disease; hemodialysis; human immunodeficiency virus.